Dialectic Therapeutics’ DT2216 Receives the US FDA’s Orphan Drug Designation for the Treatment of T-Cell Lymphoma
Shots:
- The US FDA has granted ODD to DT2216 for the treatment of T-cell lymphoma. DT2216 (IV, q3w for 4wks.) is being studied in a P-I dose-escalation study for advanced or metastatic solid tumors & hematologic malignancies who are no longer responsive to approved or accepted SoC interventions
- In preclinical studies, the therapy selectively induced the degradation of B-cell lymphoma or BCL-XL in cancer cells & stimulates the return of cellular apoptosis or sensitizes the cells to be more susceptible to CT
- The therapy was effective in multiple in vitro models as monothx. & in combination with other chemotherapeutic agents while cancer cells are less likely to develop resistance to DT2216 over other CT
Ref: PR Newswire | Image: Dialectic
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
